Drug Origin Transparency Act of 2023

Cost and committee reports

Official records Congress.gov attaches to H.R. 3810.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Ms. ESHOO, as printed in the Congressional Record (Vol. 169, No. 97, June 5, 2023, Page H2742):
  Article 1, Section 8 The single subject of this legislation is: To increase transparency in where drugs and active pharmaceutical ingredients are manufactured.
  Source: Congress.gov, Congressional Record June 5, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  159 characters

  Congress.gov bill record

  H.R. 3810, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/3810

  Record last updated by Congress.gov

  May 27, 2025

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  d36e7e752c91ae71702b9228f13522488187f1f50e60746f0f8ab5aa952566a9

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of May 27, 2025). Not every bill gets one.

From the Congress.gov bill record for H.R. 3810, last updated May 27, 2025. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.